Make it onto the Fortune Global 500 list by 2020: Chairman of GPHL

2017-11-02 18:10:37 GPHL GPHL

The Annual Meeting of the New Champions, also known as the Summer Davos, opened on June 20, 2017. The theme of the meeting is “Achieving Inclusive Growth in the Fourth Industrial Revolution”.

Guangzhou is implementing its IAB initiative, aiming at developing both advanced manufacturing processes and strategic emerging industries, such as information technology, artificial intelligence and biopharmaceuticals, and establishing a modernized industry. How should Guangzhou seize the opportunities of the Fourth Industrial Revolution?

As a successful businessperson in the Guangzhou delegation, Li Chuyuan, Chairman of Guangzhou Pharmaceutical Holdings Limited (GPHL), was interviewed on how GPHL has realized the goal of inclusive growth and facilitated the city’s development strategy.

GPHL is one of the largest Chinese medicine manufacturers. It actively focuses on innovation and reform, and transformation and upgrade of its three major businesses, striving for a leading position under Guangzhou’s IAB initiative.

Li Chuyuan, the Chairman of GPHL.

Philosophy of “Trendy TCM”

The surge of the Fourth Industrial Revolution has become overwhelming. Any industry, such as biology, precision medicine, brain science, genetic technology, implantable technologies, could prove to be the next boom in the biopharmaceutical sector. Mr. Li mentioned that this is both an opportunity and challenge for GPHL. At present, GPHL owns and is upgrading its three major businesses, including “Grand Southern TCM”, “Grand Health” and “Grand Commerce”.

GPHL promotes the philosophy of “Trendy TCM”, that is, to provide products that are in demand and to promote TCM by applying advanced manufacturing technology and the most popular and accessible marketing methods among young people. In order to expand its footprint, GPHL targets the “Grand Medical Treatment” sector and focuses on healthcare services that integrate medical treatment and health maintenance. In addition, the Group is active in the medical devices sector; establishing a medical equipment industrial park and developing implantable technologies, with emphasis on mid-to-high-end medical devices.

Meanwhile, GPHL has increased its investment in R&D and accelerated the development of new drugs. So far 13 new drugs in category 1.1 are under development, such as hepatitis B vaccine treatment, tumor preventatives and protein-based biological medication.

On this basis, GPHL has sped up the pace of expanding their global footprint and capitalization, with the focus on the internationalization of R&D, corporate culture and business, and has obtained biopharmaceutical resources from home and abroad through M&A, shareholding and other approaches.

Regarding the new business model, e-commerce is set to be one of three major business approaches followed during the 13th Five-year Plan period (2016-2020). www.GYJM.com.cn is among the first group of online drug stores to be issued with national certification.

Two Nobel Prize winners to raise the R&D standards

Guangzhou is implementing its IAB initiative, Mr. Li said that, GPHL, as the largest medicine manufacturer in China and the largest biopharmaceutical company in Guangzhou, should make every effort to become a pioneer for promoting this initiative.

GPHL has been awarded the second class National Science and Technology Progress Award for two consecutive years. It has two Nobel Prize winners, one Guangdong Province Innovation Team, 10 double-employed academicians, seven foreign expert advisors, two experts with a State Council Special Allowance and over 100 experts with PhD degree and rank of professor. The two Nobel Prize winners have raised GPHL’s international R&D standards. Dr. Ferid Murad, known as the Father of Viagra, offered professional advice to develop Jin’ge, a product similar to Viagra. He also serves as the director of GPHL’s Medical Equipment Institute.

During the Summer Davos, GPHL met executives from Gilead Sciences, Teva Pharmaceutical Industries, Pfizer, Takeda Pharmaceutical Company, with the hope of reaching agreement on partnership and making contributions to the biopharmaceutical industry in Guangzhou.

GPHL is expected to record the sales of over RMB 100 billion in 2017. By 2020, GPHL will become a world-leading pharmaceutical and healthcare enterprise that integrates pharmaceuticals, medical care, healthcare products, healthcare services, commerce and logistics with annual sales of RMB 150 billion, as well as being listed among Fortune Global 500, said Mr. Li.

(Translator: Michelle Wang; Editors: Simon Haywood, Olivia Yang, Monica Liu)

NULL